Trey Powrzanas
Primary Care · Phoenix, AZNPI 1821400755
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,550 of the $15,788 with a category attached, or 79.5%. 33 manufacturers reported payments, led by Gilead at 36.3% of the total. Reporting peaked in 2023 at $6,619 and has fallen 96.8% since, to $211 in 2025. Among primary care clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 693 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$6K
- Viiv Healthcare Company$4K
- Johnson & Johnson$957
- Merck$888
- AbbVie$800
- EMD Serono, Inc.$691
- plus $2K from 27 others
What the payments were for
- Consulting fees$1,74011%
- Speaking & faculty fees$1281%
- Travel & lodging$1,0897%
- Food & beverage$12,55079%
- Education$2812%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 174 | $5,724 |
| Viiv Healthcare Company | 229 | $4,300 |
| Johnson & Johnson | 61 | $957 |
| Merck | 41 | $888 |
| AbbVie | 41 | $800 |
| EMD Serono, Inc. | 34 | $691 |
| Novo Nordisk | 20 | $338 |
| Janssen Products, LP | 3 | $281 |
| Amgen | 15 | $274 |
| AstraZeneca | 12 | $230 |
| Abbott | 11 | $218 |
| Boehringer Ingelheim | 10 | $191 |
| Napo Pharmaceuticals Inc | 8 | $128 |
| Theratechnologies Inc. | 2 | $108 |
| Astellas Pharma US Inc | 3 | $94 |
| Lilly USA, LLC | 5 | $81 |
| Lucid Diagnostics Inc. | 2 | $75 |
| Novartis | 3 | $67 |
| Boston Scientific | 2 | $65 |
| Medtronic | 3 | $41 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| GSK | 1 | $22 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Eisai Inc. | 1 | $19 |
| Dynavax Technologies Corporation | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Vanda Pharmaceuticals Inc. | 1 | $17 |
| Seqirus USA Inc | 1 | $17 |
| Aprecia Pharmaceuticals, LLC | 1 | $16 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
| Intra-sana Laboratories | 1 | $13 |
| Acerus Pharmaceuticals Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,788 in reported general payments places this provider in the 95th percentile of 151 primary care providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 250 | $967,672 |
| DovatoDolutegravir Sodium/Lamivudine | 69 | $200,338 |
| CabenuvaCabotegravir/Rilpivirine | 25 | $154,208 |
| DescovyEmtricitabine/Tenofov Alafenam | 43 | $89,946 |
| Egrifta SvTesamorelin Acetate | 12 | $78,442 |
| TivicayDolutegravir Sodium | 32 | $74,735 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 13 | $62,261 |
| OzempicSemaglutide | 56 | $60,234 |
| JardianceEmpagliflozin | 70 | $51,680 |
| JanuviaSitagliptin Phosphate | 44 | $49,738 |
| PrezcobixDarunavir/Cobicistat | 17 | $46,069 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 13 | $43,879 |
| JulucaDolutegravir/Rilpivirine | 13 | $42,247 |
| EliquisApixaban | 51 | $40,016 |
| TrulicityDulaglutide | 32 | $31,368 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Descovy | $5,724 | $1,057,618293 claims |
| Viiv Healthcare CompanyDovato, Cabenuva, Tivicay, Juluca | $4,300 | $471,528139 claims |
| MerckJanuvia, Pifeltro, Janumet Xr | $888 | $86,76076 claims |
| Theratechnologies Inc.Egrifta Sv | $108 | $78,44212 claims |
| Janssen Products, LPSymtuza | $281 | $62,26113 claims |
| Novo NordiskOzempic | $338 | $60,23456 claims |
| Boehringer IngelheimJardiance | $191 | $51,68070 claims |
| Johnson & JohnsonPrezcobix | $957 | $46,06917 claims |
| Lilly USA, LLCTrulicity | $81 | $31,36832 claims |
| AstraZenecaFarxiga | $230 | $25,23720 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $22 | $21,91126 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $9,99113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 151 primary care providers in Arizona.
Other primary care in Phoenix
- Christine Rocks-LopezPhoenix$14K
- Elena KlimovaPhoenix$8K
- Albert VillafaniaPhoenix$8K
- Daniela HaimovPhoenix$8K
- Charity CorreaPhoenix$5K
- Cara Loveless-FaulknerPhoenix$4K
- Chelsea GreenwoodPhoenix$4K
- Kerry OliverPhoenix$2K
- Kathryn SuessPhoenix$2K
- Nahla ChircoPhoenix$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.